Panelists explore treatment strategies and the integral role of the multidisciplinary care team in optimizing outcomes in CML.
Panelists discuss a multidisciplinary approach to managing chronic myeloid leukemia (CML), using a clinical case to highlight the importance of early diagnosis, timely referral to specialized centers, and coordinated care among oncologists, nurse practitioners, and pharmacists to optimize patient outcomes.
Panelists discuss the critical role of early molecular testing and multidisciplinary collaboration—including pharmacists, nurse practitioners, and physicians—in personalizing chronic myeloid leukemia (CML) treatment, managing adverse effects, and supporting patient adherence to optimize long-term outcomes.
Panelists discuss the evolving landscape of frontline chronic myeloid leukemia (CML) treatment, highlighting asciminib’s emerging role as a preferred first-line therapy due to its favorable efficacy, tolerability, and potential to simplify treatment selection while supporting long-term goals like deep molecular response and treatment-free remission.
Panelists discuss the importance of monitoring molecular milestones in chronic myeloid leukemia (CML) to guide treatment response and eligibility for treatment-free remission (TFR), emphasizing the multidisciplinary team’s role—including pharmacists and nurses—in supporting adherence, managing adverse effects, and providing individualized patient care.
Panelists discuss a complex case of chronic myeloid leukemia (CML) progression in a younger patient, highlighting the critical importance of mutation testing, careful tyrosine kinase inhibitor (TKI) selection based on comorbidities, and adaptive treatment strategies to manage resistance and optimize outcomes.
Panelists discuss the critical role of mutation testing and individualized ponatinib dosing in managing resistant or relapsed chronic myeloid leukemia (CML), emphasizing frequent molecular monitoring and multidisciplinary care to balance treatment efficacy with toxicity.
Panelists discuss the declining role of allogeneic transplant in chronic myeloid leukemia (CML) due to advances in tyrosine kinase inhibitors (TKIs) while emphasizing ongoing challenges related to treatment tolerability, management of advanced disease, and financial toxicity that necessitate continued research and supportive care strategies.
